IN2015DN02849A - - Google Patents

Info

Publication number
IN2015DN02849A
IN2015DN02849A IN2849DEN2015A IN2015DN02849A IN 2015DN02849 A IN2015DN02849 A IN 2015DN02849A IN 2849DEN2015 A IN2849DEN2015 A IN 2849DEN2015A IN 2015DN02849 A IN2015DN02849 A IN 2015DN02849A
Authority
IN
India
Prior art keywords
pharmaceutical composition
adrenalin
antidepressant
shocks
administered
Prior art date
Application number
Other languages
English (en)
Inventor
Jean-Charles; Schwartz
Xavier; Ligneau
Laurent Francois Gerard; Landais
David; Perrin
Jeanne-Marie; Lecomte
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of IN2015DN02849A publication Critical patent/IN2015DN02849A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
IN2849DEN2015 2012-10-03 2013-10-02 IN2015DN02849A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306207 2012-10-03
PCT/EP2013/070598 WO2014053579A1 (en) 2012-10-03 2013-10-02 A combination of adrenalin with an antidepressant for use in the treatment of shocks

Publications (1)

Publication Number Publication Date
IN2015DN02849A true IN2015DN02849A (ja) 2015-09-11

Family

ID=47073380

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2849DEN2015 IN2015DN02849A (ja) 2012-10-03 2013-10-02

Country Status (31)

Country Link
US (2) US20150306065A1 (ja)
EP (1) EP2903607B1 (ja)
JP (1) JP6419074B2 (ja)
KR (1) KR102145786B1 (ja)
CN (1) CN104780916B (ja)
AU (1) AU2013326470B2 (ja)
BR (1) BR112015007524B1 (ja)
CA (1) CA2887330C (ja)
CY (1) CY1119514T1 (ja)
DK (1) DK2903607T3 (ja)
EA (1) EA030763B1 (ja)
ES (1) ES2647597T3 (ja)
HK (1) HK1211846A1 (ja)
HR (1) HRP20171442T1 (ja)
HU (1) HUE034638T2 (ja)
IL (1) IL238120B (ja)
IN (1) IN2015DN02849A (ja)
LT (1) LT2903607T (ja)
MA (1) MA37970B2 (ja)
MX (1) MX359198B (ja)
NO (1) NO2903607T3 (ja)
NZ (1) NZ707124A (ja)
PH (1) PH12015500755B1 (ja)
PL (1) PL2903607T3 (ja)
PT (1) PT2903607T (ja)
RS (1) RS56392B1 (ja)
SG (1) SG11201502645VA (ja)
SI (1) SI2903607T1 (ja)
TN (1) TN2015000126A1 (ja)
WO (1) WO2014053579A1 (ja)
ZA (1) ZA201502441B (ja)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3705942A (en) * 1969-09-29 1972-12-12 Ciba Geigy Corp Treatment of glaucoma employing imipramine or desmethylimipramine
TW200744568A (en) * 2006-02-28 2007-12-16 Verus Pharmaceuticals Inc Epinephrine dosing regimens
TW200817049A (en) * 2006-06-05 2008-04-16 Verus Pharmaceuticals Inc Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
PL2818184T3 (pl) * 2007-11-16 2019-06-28 Aclaris Therapeutics, Inc. Kompozycje i sposoby do leczenia plamicy
SE533552C2 (sv) * 2008-12-30 2010-10-26 Igeloesa Transplantation Science Ab Förfarande och lösning för behandling av en potentiell organdonator
US20100190860A1 (en) * 2009-01-09 2010-07-29 The Brigham And Women's Hospital, Inc. Methods for selectively enhancing antinociceptive potency of local anesthetics
CN101987198B (zh) * 2009-08-06 2014-08-13 北京美倍他药物研究有限公司 药物组合物

Also Published As

Publication number Publication date
HRP20171442T1 (hr) 2018-01-12
CN104780916A (zh) 2015-07-15
PL2903607T3 (pl) 2018-01-31
CY1119514T1 (el) 2018-03-07
ZA201502441B (en) 2015-12-23
HK1211846A1 (en) 2016-06-03
MA37970B1 (fr) 2016-06-30
EP2903607B1 (en) 2017-08-16
ES2647597T3 (es) 2017-12-22
KR102145786B1 (ko) 2020-08-19
SG11201502645VA (en) 2015-05-28
CA2887330A1 (en) 2014-04-10
HUE034638T2 (en) 2018-02-28
RS56392B1 (sr) 2017-12-29
KR20150093656A (ko) 2015-08-18
BR112015007524A2 (pt) 2017-07-04
JP6419074B2 (ja) 2018-11-07
JP2015536907A (ja) 2015-12-24
MA37970B2 (fr) 2017-10-31
AU2013326470A1 (en) 2015-04-30
EP2903607A1 (en) 2015-08-12
IL238120B (en) 2018-08-30
NZ707124A (en) 2017-12-22
SI2903607T1 (sl) 2017-12-29
EA201500374A1 (ru) 2015-07-30
WO2014053579A1 (en) 2014-04-10
PH12015500755A1 (en) 2015-05-25
EA030763B1 (ru) 2018-09-28
CA2887330C (en) 2021-03-09
AU2013326470B2 (en) 2017-08-24
NO2903607T3 (ja) 2018-01-13
US10952987B2 (en) 2021-03-23
US20190117614A1 (en) 2019-04-25
LT2903607T (lt) 2017-10-25
BR112015007524B1 (pt) 2022-06-21
CN104780916B (zh) 2019-02-26
PT2903607T (pt) 2017-11-14
MX359198B (es) 2018-09-19
DK2903607T3 (en) 2017-10-09
TN2015000126A1 (en) 2016-10-03
PH12015500755B1 (en) 2015-05-25
MA20150396A1 (fr) 2015-11-30
MX2015004323A (es) 2015-06-10
US20150306065A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
IN2015DN03029A (ja)
UA110354C2 (uk) Противірусні сполуки
EP2827869A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO
MX2019013123A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
CR20140405A (es) Apoptosis señal reguladores del inhibidor de quinasa
MY176489A (en) Novel tricyclic compounds as anticancer agents
JO3438B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
GT201200144A (es) Composición farmacéutica que comprende un agonista de glp-1, una insulina y metionina
EA201391033A1 (ru) Ингибиторы bace-2 для лечения метаболических расстройств
MX339533B (es) Composiciones y metodos de daclizumab (dac) del proceso de alto rendimiento (hyp).
PH12015500746A1 (en) Benzamides
CL2014001704A1 (es) Derivados de amida ciclica como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa; composicion farmaceutica que los comprende y el uso de los mismos en la prevencion o tratamiento de enfermedades tales como la diabetes.
PH12016500924A1 (en) Anti-cancer agents and preparation thereof
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
MY179576A (en) Agent for promoting in vivo absorption of hydroxytyrosol and derivatives thereof and use of same
MX2014008918A (es) Nuevos derivados de pirrolidina.
MX2013011694A (es) Analogos de taxano y abeo-taxanos.
MX348841B (es) Derivados de pirimidooxazocina como inhibidores de mtor.
IN2015DN02849A (ja)
MX369774B (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
MX2013006526A (es) Dosis de los derivados de arilsulfonamida.
UA85352U (ru) Фармацевтический продукт, содержащий налбуфин
IN2013MU03613A (ja)
UA79947U (ru) Применение 4-[4-оксо-(4H)-хиназолин-3-ил]бензойной кислоты в качестве средства с центральным обезболивающим действием